Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy

Encorafenib, a BRAF kinase inhibitor, in combination with binimetinib, a selective MEK inhibitor have known gastrointestinal adverse events; however, adverse colitis events have not been well studied. We report a case series of 4 patients with melanoma who developed inflammatory colitis after BRAF a...

Descripción completa

Detalles Bibliográficos
Autores principales: Issac, Aaron G., Szafron, David, Wei, Dongguang, McQuade, Jennifer L., Wang, Yinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247533/
https://www.ncbi.nlm.nih.gov/pubmed/35949237
http://dx.doi.org/10.1159/000525012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247533/
https://www.ncbi.nlm.nih.gov/pubmed/35949237
http://dx.doi.org/10.1159/000525012

Ejemplares similares